FOLFOX 2d

Phase 3Small molecule

SSichuan Baili Pharmaceutical Co., Ltd.

FOLFOX 2d is one of 142 small molecule programs targeting Gastric Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

141

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric AdenocarcinomaActive, not recruiting

Intestinal CancerActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Gastric AdenocarcinomaPhase 3

Active, not recruiting

Intestinal CancerPreclinical

Active, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

FOLFOX 2d

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

3 2

Ibrance

Pfizer

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Cysteine Hydrochloride

Novartis

Preclinical

1 6

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 7

Doptelet

AAkarx

Preclinical

1 8

Opdivo

Bristol-Myers Squibb

Preclinical

2 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 10

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Unresectable

NCT05476432

Q2 2028

Phase 3Recruiting

Gastric Cancer

NCT06346197

Q3 2029

Phase 3Not yet recruiting

Locally-Advanced Rectal Cancer

NCT03975049

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B

Completed·SSun Yat-sen University·Phase 2·NCT03048123·79 enrolled

HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.

Completed·SSun Yat-sen University·Phase 3·NCT02973685·315 enrolled

Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma

Completed·SSun Yat-sen University·Phase 2·NCT02981498·35 enrolled

Sorafenib2 trials

HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC

Unknown status·SSun Yat-sen University·Phase 2·NCT03812783·100 enrolled

Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC

Completed·SSun Yat-sen University·Phase 3·NCT02774187·247 enrolled

Unresectable1 trial

HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study

Recruiting·SSun Yat-sen University·Phase 3·NCT05476432·300 enrolled

Chemotherapy1 trial

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

Terminated·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT05039944·7 enrolled

Neoadjuvant Chemotherapy1 trial

NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer

Completed·CCanadian Cancer Trials Group·Phase 2·NCT03259035·58 enrolled

7 more indications

PD-1antibody1 trial

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Withdrawn·SSun Yat-sen University·Phase 2·NCT03803254

Locally-advanced Rectal Cancer1 trial

Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Not yet recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 3·NCT03975049·933 enrolled

Intestinal Cancer1 trial

the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin

Unknown status·—··NCT05494320·120 enrolled

Colon Cancer1 trial

IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting

Completed·UUNICANCER·Phase 3·NCT02967289·792 enrolled

Metastatic Colorectal Cancer1 trial

Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer

Recruiting·FFudan University·Phase 3·NCT04516681·400 enrolled

Carcinoma, Hepatocellular1 trial

Prospective, Single-arm, Multicenter Clinical Study of Hepatic Artery Infusion Chemotherapy With Donafenib for Adjuvant Treatment of HCC Patients With High Risk of Recurrence After Hepatectomy.

Completed·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04962958·30 enrolled

Gastric Cancer1 trial

A Multicenter, Randomised, Comparative, Open-label Phase III Aiming to Compare the Survival of Patients With Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Treated by a Combination of Immune Checkpoint Inhibitors (Botensilimab + Balstilimab) Versus the Standard of Care (FOLFOX/XELOX + Nivolumab)

Recruiting·CCentre Leon Berard·Phase 3·NCT06346197·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for FOLFOX 2d. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFOX 2d compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFOX 2d. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Baili Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSichuan Baili Pharmaceutical Co., Ltd.

FOLFOX 2d

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Q3 2029

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

Sorafenib2 trials

Unresectable1 trial

Chemotherapy1 trial

Neoadjuvant Chemotherapy1 trial

PD-1antibody1 trial

Locally-advanced Rectal Cancer1 trial

Intestinal Cancer1 trial

Colon Cancer1 trial

Metastatic Colorectal Cancer1 trial

Carcinoma, Hepatocellular1 trial

Gastric Cancer1 trial

References

Drug Info

Quick Facts

Related News